The PCI Biotech and Ultimovacs collaboration awarded NOK 500,000 from Innovation Norway

The PCI Biotech and Ultimovacs collaboration awarded NOK 500,000 from Innovation Norway

Oslo (Norway), 6 January 2017 – PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company, and Ultimovacs, a pharmaceutical company developing novel immunotherapy against cancer, today announced that they are awarded NOK 500,000 for further development of the existing preclinical research collaboration. The purpose of the collaboration is to utilise the companies’ complementary scientific platforms to explore potential synergies and the grant will support these activities. The Innovation Norway grant of NOK 500,000 is awarded for 2017 and the grant is made available through Oslo Cancer Cluster a Norwegian Centre of Expertise.

Please see attached press release for further details.

Contact information:
PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo, Norway. www.pcibiotech.com
Per Walday, CEO, pw@pcibiotech.no, Mobile: +47 917 93 429.

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

 

International press event created attention all over Europe

Early September Oslo Cancer Cluster hosted an international press event with our member Abbvie. Over 20 journalists from all over Europe came to the Oslo Cancer Cluster Incubator and Innovatiion Park to learn more about the latest technological and scientific developments within cancer research.

 

The journalists attended a full day meeting at the Innovation Park which included a lab session with Ullern High School students and researchers at the Cell Therapy Lab, whom showed them how cells are programmed to kill cancer cells. Gunnar Sæter, Head of the Cancer Institute, introduced the journalists to the topic of precision medicine in oncology with Oslo Cancer Cluster members SAS and IBM demonstrating the latest developments within data collection and analysis. Giske Ursin, Director of  Cancer Registry Norway, explained how the unique health data we have in Norway provides a large unused potential within oncology.

 

The journalist also got to meet Deborah Simms, journalist and cancer survivor and her doctor, John Gribben from the Barts Cancer Institute. They explained the role of collaboration in the diagnostics and treatment of patients with unmet need.

 

You can see the invitation video for the event here:

See the video from the event made by students at Ullern High School here:

More about Deborah Simms and her patient journey here:

News stories related to the event:

Innovasjonsrammen 2016

Det overordnede målet med Innovasjonsrammen 2016 er å stimulere til økt innovasjon gjennom flere felles innovasjons- og forskningsprosjekter mellom bedrifter.

Midlene skal brukes til mobilisering av utviklingsprosjekter og til idé- og prosjektutvikling (konseptualisering). Innovasjonsrammen 2016 skal bidra til at samarbeidsprosjektene kommer i posisjon til å få finansiering gjennom Forskningsrådets og Innovasjon Norges ordinære ordninger eller fra private investorer.

Oslo Cancer Cluster har fått tildelt en rammebevilgning på en million kroner, som kan trekkes på etter saksbehandling og innvilgning fra Innovasjon Norge. Klyngen forestår selv prioriteringer av egne prosjekter innenfor rammen ved at daglig leder eller en med mandat fra daglig leder anbefaler søknaden på vegne av klyngen. Prioriteringene skal være gjort i samråd med klyngens styre.

Prosjektene må innfri kravene for støtte til eksperimentell utvikling (FoUI) i statsstøtteregelverket. Et av kravene er at støtten kun kan gis til èn bedrift eller ett kompetansesenter. Søker kan imidlertid få dekket kostnader ved kjøp av tjenester fra partnere i samarbeidsprosjektet.

Innovasjonsrammen stiller krav til at midlene kun benyttes til samarbeidsprosjekter der minimum to virksomheter inngår (merk; minst en av bedriftene må være partner eller medlem i klyngen).

Tilskudd fra Innovasjonsrammen 2016 gis i tråd med regelverket for støtte til eksperimentell utvikling (FoUI-støtte) i statsstøtteregelverket. Støtten skal gis på områdene mobilisering og konseptualisering. Regelverket åpner for 25-45% støtte avhengig av bedriftenes størrelse samt 15% i samarbeidsbonus.

Interesserte bedrifter i Oslo Cancer Cluster bes ta kontakt med bk@occincubator.com for mer informasjon og søknadsskjema. Søknadene vil vurderes av et ekspertpanel, og innleveringsfristen for søknaden er 7.september.

På vegne av Oslo Cancer Cluster

Bjørn Klem

Nadine Lohs hired as Operation Manager

The Oslo Cancer Cluster Incubator has recruited Nadine Lohs to be responsible for the operation of the Incubator from 1st August.

Nadine Lohs is from Austria and has recently completed her Master of International Health and Social Management at the Management Center Innsbruck. She has had an internship at Oslo Cancer Cluster Incubator this Spring.

Contact details:

E-mail: nadine@occincubator.com

Phone: 90 76 23 63

Thermo Fisher Scientific will create Google-like envionment for biotech in the Oslo Cancer Cluster Incubator

Thermo Fisher Scientific will rent over 800m2 in the Oslo Cancer Cluster Incubator. Here, the company will create a creative Google-like environment with a particular focus on diagnostics and the development of new treatments using cancer immunotherapy.

 

 Thermo Fisher Scientific is one of Norway´s leading biotechs and among the most profitable. The company is expanding and during the first quarter of 2016 the entire management team, production team and parts of the R&D milieu will move to the Oslo Cancer Cluster Incubator. Here, 800m2 will be set up like a creative Google-like office space.

– We are really pleased that Thermo Fisher Scientific chooses to move into Oslo Cancer Cluster Incubator. The company, which initially was established as Dynal in 1986, has played a vital role in Norwegian biotech with the development of «Dynabeads» that is used all over the world. Their record of accomplishment of bringing innovative products to the market is impressing. For the environment in the incubator it is crucial to have a global, experienced actor present, says Bjørn Klem, CEO Oslo Cancer Cluster Incubator.

 

Strong in immunotherapy

The overall aim of the Oslo Cancer Cluster Incubator is to contribute to the successful development of oncology biotechs so that they may reach the market with their innovative treatments against cancer. The cancer R&D milieu in Norway in general is strong within cancer immunotherapies, which is also the case with the incubator companies.

– Thermo Fisher´s «Dynabeads» is used in basic research, in billions of diagnostic tests as well as in immunotherapy all over the world. Innovation and further applications is developed in close collaboration with research environments, clinics and industrial partners. Oslo Cancer Cluster has become one of the leading innovation clusters and we would like to take an active role in further developing the cluster. We think that co-localisation with the milieu in the incubator will be a catalyst for our growth and innovation in the future, says Ole Dahlberg, CEO Thermo Fisher Scientific in Norway.

 

Facts: 

Thermo Fisher Scientific:
Thermo Fisher Scientific in Norway (former Dynal Biotech) was established in 1986. The company focuses on the diagnostics market as well as the development of innovative immunotherapeutics, especially within oncology. The client portfolio features many of the world’s largest pharma and diagnostics companies. In 2014 the company had 180 employees and a turn-over of 760 MNOK. The company have production units both in Oslo and Lillestrøm. The Norwegian company is a subsidiary to Thermo Fisher Scientific which is listed on NYSE. www.thermofisher.com


In Norwegian:

Thermo Fisher Scientific inn i Oslo Cancer Cluster Inkubator: Styrker miljøet rundt immunterapi mot kreft

Thermo Fisher Scientific skal leie over 800m2 i Oslo Cancer Cluster Incubator. Selskapet skal skape et kreativt ‘Google-aktig landskap’ innen bioteknologi med særlig fokus på diagnostikk og utvikling av nye former for behandling ved bruk av immunterapi.

Thermo Fisher Scientific er et av Norges største biotekselskap og blant de mest lønnsomme. Selskapet utvider og flytter nå hele ledergruppen og produktorganisjasjonen, samt deler av sitt forsknings- og utviklingsmiljø over til Oslo Cancer Cluster Inkubator. I 5.etasje i inkubatoren skal over 800m2 omgjøres til et kreativt landskap for ansatte i selskapet med fokus på forskning og utvikling innen diagnostikk og immunterapi mot kreft.

– Vi er utrolig glade for at Thermo Fisher Scientific velger å flytte inn i Oslo Cancer Cluster Inkubator. Selskapet, som startet som Dynal i 1986 er en viktig del av norsk bioteknologihistorie med sin utvikling av «Dynabeads»  basert på Ugelstadkulene. De har vist gjentatte ganger at de kan kommersialisere god forskning. Det vil bety mye for resten av miljøet i inkubatoren å ha med en så erfaren aktør med global tilstedeværelse, sier Bjørn Klem som er daglig leder i Oslo Cancer Cluster Incubator.

 

Viktig for et Norge i omstilling

Oslo Cancer Cluster Inkubator skal bidra til at flere selskaper lykkes med å utvikle sin behandling av ulike kreftformer. Immunterapi mot kreft er en helt ny måte å behandle kreft på der kroppens eget immunforsvar aktiveres for å bekjempe kreftcellene. Miljøet i inkubatoren er særlig sterke innen dette fagfeltet, som blir ytterligere styrket ved at immunmonitoreringsenheten ved seksjon for celleterapi ved Oslo universitetssykehus, Radiumhospitalet flytter inn med syv ansatte i tillegg til Thermo Fisher Scientific.

 

– Thermofisher sine «Dynabeads» brukes i dag innen grunnforskning, til milliarder av diagnostiske tester og nå innen immunterapi. Innovasjon og applikasjonsutvikling skjer i nært samarbeid med forskningsmiljøer, klinikker, og industrielle partnere. Oslo Cancer Cluster har demonstrert høye ambisjoner og gjennomføringsevne på å bli en av de ledende innovasjonsklyngene og vi ønsker å være en del av det. Samlokalisering og felles aktiviteter med klinikken og andre selskaper tror vi er en katalysator for vår vekst og innovasjonsgrad fremover, sier Ole Dahlberg, administrerende direktør i Thermo Fisher Scientific i Norge.

 

– Statsminister Erna Solberg sa da hun åpnet Oslo Cancer Cluster Innovasjonspark og inkubator i august i år at helseindustri er en industri med dobbel gevinst: Fremskrittene som gjøres bidrar til velferd og helse samtidig som de skaper verdier og arbeidsplasser. Vi er overbevist om at det norske kreftforskning- og utviklingsmiljøet kan bety mye for et Norge i omstilling, samtidig som vi utvikler morgendagens kreftbehandling, sier Ketil Widerberg, daglig leder i Oslo Cancer Cluster.

 

Kontaktpersoner:

Oslo Cancer Cluster Inkubator: Bjørn Klem, daglig leder: e-post: bk@occincubator.com mobil: 924 161 56

Oslo Cancer Cluster: Ketil Widerberg, daglig leder: e-post: kw@oslocancercluster.no, mobil: 915 77 990

Thermo Fisher Scientific: Ole Dahlberg, adm.dir, e-post: ole.dahlberg@thermofisher.com, mobil 91108260 eller Geir Hetland, finansdirektør, e-post: geir.hetland@thermofisher.com, mobil: 98218280

 

Thermo Fisher Scientific:
Thermo Fisher Scientific i Norge (tidl Dynal Biotech) ble etablert i 1986. Selskapet har fokus på det diagnostiske markedet samt utvikling av nye former for immunterapi spesiellt innenfor kreftområdet. Kundeportoføljen består av mange av verdens største pharma og diagnostiske selskaper i verden. I 2014 hadde selskapet 180 ansatte og omsatte for 760 millioner. Selskapet har produksjonslokaler både i Oslo og Lillestrøm. Det norske selskapet er et datterselskap til Thermo Fisher Scientific som er et børsnotert selskap på NYSE. www.thermofisher.com

 

 

 

 

 

 

 

 

 

 

HealthCap opens office in Oslo Cancer Cluster Incubator

HealthCap, a leading life science venture capital firm, has opened office in the newly established incubator in the Oslo Cancer Cluster Innovation Park. HealthCap also becomes a member of the Oslo Cancer Cluster.

 

HealthCap recognizes the emerging life sciences industry in Norway. “The strong environment created in the dedicated oncology cluster, bringing together all parts of the oncology value chain at the world renowned Radiumhospitalet, holds promise to play an important role in the development of the next generations of oncology treatments. We look forward to take part in and contribute to this important endeavor”, says Björn Odlander, managing partner of HealthCap.

HealthCap has retained Ludvik Sandnes to supervise the Norwegian operations. Ludvik Sandnes is a special advisor to HealthCap and has more than 40 years of experience from international corporate finance and asset management. He is currently the chairman of the listed Norwegian oncology company Nordic Nanovector AS.

 

HealthCap will host a seminar at the Oslo Cancer Cluster Innovation Park on December 9th at 12.30.
Please sign up here, the program will be published shortly.

The CEO of Oslo Cancer Cluster and Chairman of the Board of Oslo Cancer Cluster Incubator, Ketil Widerberg says “We are extremely happy to have HealthCap on board both in the Oslo Cancer Cluster and in the Incubator. HealthCap´s track record of investing in life science is impressing, and their competence and network will be valuable for further building a viable oncology industry based on excellent cancer research at Norwegian academic institutions.”

HealthCap invests in companies developing targeted therapies for rare diseases, cancer and genetic diseases, among others. HealthCap was the lead investor in the Norwegian oncology company Algeta, which was acquired by Bayer for USD 2.9 bn, and is the largest shareholder in the Norwegian oncology companies Nordic Nanovector AS and Targovax AS.

Purely focused on oncology, the Oslo Cancer Cluster Innovation Park and Incubator, will ensure that bright ideas in the lab benefit cancer patients faster than today.

 

For more information, please contact:

Björn Odlander, managing partner HealthCap,  email: bjorn.odlander@healthcap.eu, phone: +46 8 442 58 50

Johan Christenson, partner HealthCap, email: johan.christenson@healthcap.eu, phone: +46 8 442 58 50

Ketil Widerberg, CEO Oslo Cancer Cluster and Chairman of the Board Oslo Cancer Cluster Incubator, email: kw@oslocancercluster.no, phone: +47 915 77 990

 

Facts:

HealthCap:
HealthCap is a leading European venture capital firm investing exclusively and globally in life sciences. A cornerstone of the strategy is to invest in companies developing therapeutic interventions that have the potential to significantly improve patient outcomes. HealthCap backs companies developing targeted therapies for rare diseases, orphan drugs, cancer and genetic diseases, among others. The HealthCap team of ten partners, five of whom are MD PhDs, has established its reputation as one of Europe’s preeminent life science specialists amongst VCs and entrepreneurs. See more at: www.healthcap.eu

 

Oslo Cancer Cluster
Oslo Cancer Cluster is a strong biotech cluster well positioned in the global oncology industry. The cluster is particularly strong in immuno-oncology and works to release the potential that lies within Norwegian oncology registries and bio banks. 70 members make up the cluster and represent the entire oncology value chain. www.oslocancercluster.no

 

Oslo Cancer Cluster Incubator
Oslo Cancer Cluster Incubator offers lab and office space to researchers and biotechs developing cancer treatments, as well as companies offering competence, services and an international network crucial to succeed in this globally competitive area. The incubator´s over all aim is to develop more companies based on excellent cancer research as well as to contribute to their success. Today, more than X companies are part of the incubator. www.occincubator.com

 

Oslo Cancer Cluster Innovation Park AS

Total space: 36 000 m²

Vision: The vision of the Oslo Cancer Cluster Innovation Park is to create Europe’s leading environment for education, research and industry within oncology, while also shortening the time it takes to develop new cancer medication and diagnostics.

Tenants: Oslo University Hospital, The Institute for Cancer Genetics and Informatics, Norwegian Cancer Registry, Oslo Cancer Cluster SA, Oslo Cancer Cluster Incubator AS, The Norwegian Radium Hospital Research Foundation, The Oslo Hospital Pharmacy, Ullern High School and leading Norwegian biotech companies such as Ultimovacs and PCI Biotech.

Owners: OBOS, Industrifinans, Radium Hospital Foundation, Utstillingsplassen Eiendom, Oslo Cancer Cluster and Oslo Cancer Cluster Incubator.

Opened officially August 24 2015 by the Prime Minister of Norway, Erna Solberg.

www.occinnovationpark.com

 

Oslo Cancer Cluster Incubator: Hottest bioincubator in the Nordics

According to The European Biotech News Website, Oslo Cancer Cluster Incubator is ranked as the hottest bioincubator in the Nordics as well as the 6th hottest bioincubator in Europe. The Top 10 ranking is subject to several criteria. You may read the whole list here.

Oslo Cancer Cluster Incubator just opened its premises in the Oslo Cancer Cluster Innovation Park August this year and is home to around 20 companies,  instituitons and consultants.

The incubator´s ultimate goal is to contribute to the succesful commercialisation of cancer research performed in Norway. This will provide patients with new cancer treatments and at the same time build a much needed knowledge based health industry in Norway.

 

Oslo Innovation Week opening will be streamed

Oslo 18.10.2014, Oslo Innovation Week. Banners at Vulkan. Photo: Gorm K. Gaare

Oslo Innovation Week will be opened today, Monday October 12 at 12 o´clock. The opening is streamed and may be watched here: https://feat.fm/oiw/. Both the Minister of Finance Siv Jensen, and the Minister of Trade and Industry, Monica Mæland will be present at the opening to launch a new plan for Norwegian entrepreneurship. 

 

Oslo Innovation Week will go on the whole week – see all about it on the official website here: www.oiw.no. Follow and join discussions on Social Medias using #oiw.
At our Events page, you may see which seminars Oslo Cancer Cluster is engaged in.

 


In Norwegian:

Finansminister Siv Jensen og næringsminister Monica Mæland vil delta på åpningen av Oslo Innovation Week og lansere gode nyheter for alle Norges entreprenører og gründere.

For alle de som ikke har mulighet til å delta på selve åpningen i Operaen i Oslo så vil den bli streamet på:  https://feat.fm/oiw/. Sendingen starter mandag kl. 12. I statsbudsjettet foreslår regjeringen tiltak for tilsammen 400 millioner “for å få frem gode gründere”.  Hva vil statsrådene presentere? Delta i debatten og bli med live!

 

 K Teams Boston: 9-20 November, 2015.

Opportunity for Oslo Cancer Cluster SMB´s: K Teams is a two week, intensive entrepreneurial training program in Boston and Cambridge. It is a great way to get a company started in the US. Please go to the following link for more information: http://kendall-teams.com/

The team behind the program is a seasoned, experienced group who have helped others companies make a successful entry into the US.  Boston is one of the most vibrant medical technology and bio/pharma regions in the US.

For more info:

Ron Sutherland, Launch in US Alliance: +1 617-407-0722 // rsutherland@launchinus.com

Oslo Cancer Cluster Incubator filling up

12 companies will have offices and lab in Oslo Cancer Cluster Incubator from August on. Bjørn Klem, General Manager of the Incubator, anticipates full house by January 2016.

– If each and every company we have given a quote so far, accepts, we actually are over booked. As of now, we have a good mix of companies. We look forward to have even more start-ups as a result of the activity in Oslo Cancer Cluster Innovation Park and the increased focus on commersialization of cancer research the building represents, says Klem.

The companies will start moving into the Incubator the first week of August, and from then on it is business 24/7. The Oslo Cancer Cluster Managament Team will support the incubator companies with competence within business development, communication, partnering, investor contacts and so on thorugh Oslo Cancer Cluster´s extensive network.

 

Overview Oslo Cancer Cluster Incubator companies as of mid-June:
See profiles of the companies on the Oslo Cancer Cluster Incubator website

  • DNB
  • Curida
  • Intersint
  • Ultimovacs
  • Inven2
  • Lifandis
  • Medivir
  • Pharmalink
  • Normetrix
  • Lytix Biopharma
  • Radium Hospital Research Foundation
  • Oslo Cancer Cluster Management Team